Due to the fact that SGK1 has been associated with drug resistance in several types of cancer [206], targeting of SGK1 in combination with ICIs can provide a potential synergy because of both tumor cell-intrinsic and -extrinsic effects. The gene discussed is SGK1; the disease is neoplasm.